Clinical Trial Update: Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating zoledronic acid to prevent bone loss in men with prostate cancer undergoing androgen deprivation therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Prostate Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Bone Loss, Prostate Cancer | Phase 2 | Status: COMPLETED